Forbes February 25, 2025
GLP-1 drugs such as Ozempic and Mounjaro are a revolution, not a trend. These weight loss drugs are one of the hottest markets in healthcare, and there’s been a dramatic surge in the number of Americans using them in February 2025. Many people incorporated these medications into their New Year’s resolutions to achieve weight loss goals.
Reports suggest around 26% of Americans plan to use GLP-1 medications for weight loss. UBS estimates that 40 million people will be on GLP-1s by 2029, with 44% in the US. This translates into $126 billion in sales by 2029, a 2023-2029 sales CAGR of 30%.
Hims & Hers’ Super Bowl commercial that featured its compounded weight loss offerings resulted in a 650% spike...
Today's Sponsors
Today's Sponsor